As­traZeneca's COPD triple ther­a­py slammed by CRL — falling fur­ther be­hind GSK

4 years ago
R&D

Be­yond BR­CA: As­traZeneca rounds out ES­MO with a case for ex­pand­ed bio­mark­er in prostate can­cer

4 years ago
R&D
Pharma

A PhI­II Tecen­triq win? Not so much, it turns out, as Roche spells out weak da­ta on blad­der can­cer

4 years ago
R&D

Agios lines up sol­id PhI­II da­ta to back Tib­sovo's use in bile duct can­cer — ahead of planned sN­DA

4 years ago
R&D
Pharma

Mer­ck­'s top can­cer team basks in the warm light of pos­i­tive Keytru­da da­ta from a land­mark study for hard-to-treat breast can­cer

4 years ago
R&D
Pharma

No­var­tis, Eli Lil­ly mar­quee pos­i­tive sur­vival da­ta for CDK 4/6 fran­chis­es — but can they ac­tu­al­ly beat Pfiz­er's block­buster?

4 years ago
R&D
Pharma

Bank­ing on Op­di­vo/Yer­voy com­bo, Bris­tol-My­ers Squibb teas­es out Check­mate-227 again at ES­MO

4 years ago
R&D
Pharma

As­traZeneca her­alds Tagris­so's OS lead over old TKIs in lung can­cer niche

4 years ago
R&D
Pharma

PRI­MA vs PAO­LA: GSK and Mer­ck/As­traZeneca square off in a high-pro­file PARP show­down at ES­MO

4 years ago
R&D
Pharma

Seat­tle Ge­net­ic­s' armed an­ti­body scores high in front­line blad­der can­cer, tak­ing cen­ter stage at ES­MO

4 years ago
R&D

An­oth­er big bio­phar­ma merg­er runs in­to an­oth­er snag at the FTC. What now?

4 years ago
Deals
Bioregnum

Bris­tol-My­ers Squibb boasts im­pres­sive 5-year melanoma OS da­ta on Op­di­vo/Yer­voy com­bo, though it still can't pin­point who should take it

4 years ago
R&D

Am­gen isn’t wow­ing ES­MO with the lat­est KRAS G12C up­date — but maybe there are more im­por­tant is­sues at stake

4 years ago
R&D

Bris­tol-My­ers Squib­b's Op­di­vo could­n't top­ple Nex­avar in HCC — but will bet­ter safe­ty pro­file win over physi­cians?

4 years ago
R&D
Pharma

Deer­field bets on New York City, blue­prints $635M biotech hub in mid­town Man­hat­tan

4 years ago
Startups

Deep im­pact: Drugs to watch in Q3 — PBM analy­sis

4 years ago
R&D
Pharma

GSK in­fus­es $120M in­to next-gen man­u­fac­tur­ing fa­cil­i­ties at Up­per Meri­on, PA

4 years ago
Pharma

Is the FTC about to force Roche to di­vest a key he­mo­phil­ia pro­gram be­fore green-light­ing Spark buy­out?

4 years ago
Deals

Cana­di­an star re­searcher Bren­dan Frey bran­dish­es Deep Ge­nomic­s' first AI-dis­cov­ered drug

4 years ago
AI
Discovery

'Worse than ever,' Boston's biotechs stare down traf­fic cri­sis — prompt­ing call for more re­mote work­ing, flex hours

4 years ago
Pharma

Reg­u­la­tors throw up an­oth­er hur­dle to Roche’s $4.3B Spark ac­qui­si­tion as ques­tions per­co­late over he­mo­phil­ia mar­ket dom­i­na­tion

4 years ago
Deals
Cell/Gene Tx

No­var­tis ac­cus­es 2 AveX­is founders of al­ter­ing da­ta, stonewalling probe — but ex-CSO blasts back

4 years ago
Pharma
Cell/Gene Tx

Is Re­gen­eron los­ing its R&D mys­tique? An­a­lyst dis­counts big biotech’s run­ner-up de­vel­op­ment strat­e­gy in an in­creas­ing­ly com­modi­tized world

4 years ago
R&D

Lund­beck’s Deb­o­rah Dun­sire didn’t just want an ex-US deal for Alder’s mi­graine drug. She want­ed the whole world

4 years ago
Deals
First page Previous page 156157158159160161162 Next page Last page